Nikolay Novitski/LinkedIn
May 5, 2026, 16:28
Nikolay Novitski: A New Era in Cardiovascular Prevention
Nikolay Novitski, Deputy chief physician, Associate professor Kaluga university, Board member Russian HF society, shared a post on X:
”Lipoprotein(a), or Lp(a), is an important cardiovascular risk factor that is largely unaffected by lifestyle changes or statin therapy.
Emerging therapies include:
- Pela (ASO) – approximately an 80 percent reduction (expected in 2026)
- Olpa (siRNA) – approximately a 71 to 101 percent reduction (expected in 2026)
- Lepo (siRNA) – approximately a 94 percent reduction, with effects lasting up to 1.5 years after a single injection
- Muva (oral) – approximately an 86 percent reduction in Lp(a)
Important note:
- Very low Lp(a) levels may be associated with an increased risk of type 2 diabetes.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy